patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_312303 | REC_0013001 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.4 | 65 | male | 1 | 59 | 7.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:36:00.210442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280534 | REC_0013002 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11 | 69 | female | 0 | 22 | 5.9 | 2 | osimertinib 80 mg daily | 24.2 | false | MSI-H | 2026-03-15T05:36:00.210757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655207 | REC_0013003 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 2.5 | 71 | female | 1 | 72 | 7.1 | 7 | pembrolizumab 200 mg q3w | 6.4 | true | MSS | 2026-03-15T05:36:00.211039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884365 | REC_0013004 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7 | 48 | female | 0 | 61 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:36:00.211346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934595 | REC_0013005 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 8 | 67 | female | 0 | 10 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:36:00.211693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573114 | REC_0013006 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 7.7 | 80 | male | 1 | 9 | 6.2 | 6 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:36:00.212005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523569 | REC_0013007 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 16.3 | 81 | female | 2 | 15 | 4.5 | 7 | osimertinib 80 mg daily | 9.7 | true | MSS | 2026-03-15T05:36:00.213348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475585 | REC_0013008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 18.1 | 80 | male | 2 | 14 | 5.2 | 5 | entrectinib 600 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:00.213758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452341 | REC_0013009 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 3.6 | 71 | female | 1 | 22 | 6.3 | 7 | pembrolizumab 200 mg q3w | 7.9 | true | MSS | 2026-03-15T05:36:00.214168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316928 | REC_0013010 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.6 | 68 | female | 1 | 49 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.7 | true | MSS | 2026-03-15T05:36:00.214474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684697 | REC_0013011 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.6 | 72 | male | 3 | 64 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.7 | false | MSS | 2026-03-15T05:36:00.214766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101401 | REC_0013012 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 18.2 | 65 | female | 1 | 16 | 6 | 5 | osimertinib 80 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:36:00.215080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825538 | REC_0013013 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.2 | 59 | female | 0 | 19 | 4.3 | 5 | entrectinib 600 mg daily | 6.5 | false | MSS | 2026-03-15T05:36:00.215413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284303 | REC_0013014 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 15 | 6.5 | 85 | female | 0 | 23 | 3.4 | 1 | pembrolizumab 200 mg q3w | 19 | true | MSS | 2026-03-15T05:36:00.215906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880044 | REC_0013015 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.3 | 76 | female | 2 | 21 | 6.5 | 6 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:00.216723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461066 | REC_0013016 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 15.5 | 73 | male | 2 | 11 | 5.7 | 1 | alectinib 600 mg BID | 25.7 | true | MSS | 2026-03-15T05:36:00.217136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269872 | REC_0013017 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.9 | 63 | male | 0 | 17 | 5.5 | 6 | pembrolizumab 200 mg q3w | 16.2 | true | MSS | 2026-03-15T05:36:00.217480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184881 | REC_0013018 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 9.3 | 72 | female | 0 | 18 | 2.5 | 5 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:36:00.217780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607412 | REC_0013019 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.9 | 60 | female | 0 | 41 | 5.7 | 4 | pembrolizumab 200 mg q3w | 14.6 | true | MSS | 2026-03-15T05:36:00.218084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738714 | REC_0013020 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.6 | 76 | female | 1 | 29 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:36:00.218424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947237 | REC_0013021 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.6 | 80 | male | 2 | 38 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.3 | true | MSS | 2026-03-15T05:36:00.218735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110055 | REC_0013022 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 6.8 | 58 | male | 0 | 11 | 7.8 | 5 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:36:00.219062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161274 | REC_0013023 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 17.6 | 53 | male | 0 | 21 | 6.6 | 6 | osimertinib 80 mg daily | 20.4 | true | MSI-H | 2026-03-15T05:36:00.219383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416741 | REC_0013024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 22.3 | 72 | female | 2 | 17 | 5.1 | 3 | alectinib 600 mg BID | 15 | true | MSS | 2026-03-15T05:36:00.219700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193350 | REC_0013025 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 5.5 | 71 | female | 1 | 20 | 5.2 | 1 | osimertinib 80 mg daily | 23.1 | true | MSS | 2026-03-15T05:36:00.219988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539708 | REC_0013026 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 13.1 | 76 | female | 1 | 7 | 3.3 | 2 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:00.220366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873798 | REC_0013027 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.4 | 71 | male | 1 | 60 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:00.221015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665564 | REC_0013028 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.6 | 72 | female | 1 | 55 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:36:00.221399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430537 | REC_0013029 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.3 | 78 | female | 1 | 6 | 4.1 | 5 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:36:00.221719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519089 | REC_0013030 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 12 | 8.7 | 81 | female | 1 | 72 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:36:00.222034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597803 | REC_0013031 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.1 | 74 | female | 2 | 47 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:36:00.222322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927842 | REC_0013032 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 16.2 | 72 | female | 2 | 19 | 5.5 | 1 | osimertinib 80 mg daily | 10.3 | true | MSS | 2026-03-15T05:36:00.222633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532362 | REC_0013033 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 5.3 | 74 | female | 2 | 0 | 5.4 | 4 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:00.222941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103278 | REC_0013034 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.5 | 80 | female | 1 | 6 | 4.5 | 5 | alectinib 600 mg BID | 10.6 | false | MSI-H | 2026-03-15T05:36:00.223265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960355 | REC_0013035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13 | 60 | male | 1 | 16 | 5.4 | 6 | entrectinib 600 mg daily | 7.1 | true | MSI-H | 2026-03-15T05:36:00.223598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313341 | REC_0013036 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.5 | 63 | male | 0 | 18 | 6.7 | 8 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:36:00.223947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934317 | REC_0013037 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 2.1 | 74 | male | 1 | 44 | 8.4 | 8 | pembrolizumab 200 mg q3w | 8.6 | true | MSS | 2026-03-15T05:36:00.224767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438804 | REC_0013038 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 11.5 | 62 | male | 1 | 18 | 5.5 | 6 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:36:00.225172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851084 | REC_0013039 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.9 | 65 | female | 1 | 10 | 5.1 | 5 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:00.225556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321475 | REC_0013040 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.8 | 61 | female | 0 | 14 | 7.9 | 7 | entrectinib 600 mg daily | 10.8 | false | MSS | 2026-03-15T05:36:00.226106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350823 | REC_0013041 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 10.8 | 66 | female | 0 | 12 | 5.6 | 0 | osimertinib 80 mg daily | 23.1 | false | MSS | 2026-03-15T05:36:00.226504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139420 | REC_0013042 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.1 | 65 | female | 0 | 23 | 4.6 | 6 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:36:00.226835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149499 | REC_0013043 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10.5 | 69 | female | 0 | 15 | 6.3 | 1 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:36:00.227153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460719 | REC_0013044 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 12.3 | 76 | female | 2 | 19 | 6.5 | 0 | sotorasib 960 mg daily | 32.6 | false | MSI-H | 2026-03-15T05:36:00.227459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663193 | REC_0013045 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 13.5 | 60 | female | 0 | 17 | 5.2 | 3 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:36:00.227758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635687 | REC_0013046 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 16 | 64 | female | 0 | 16 | 5.1 | 8 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:36:00.228051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910638 | REC_0013047 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.6 | 57 | female | 0 | 14 | 4.2 | 6 | entrectinib 600 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:00.228465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143471 | REC_0013048 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.8 | 82 | female | 2 | 11 | 4.8 | 5 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:00.228828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430146 | REC_0013049 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 17.2 | 73 | female | 1 | 13 | 5.8 | 0 | sotorasib 960 mg daily | 34 | false | MSI-H | 2026-03-15T05:36:00.229159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959381 | REC_0013050 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.6 | 60 | male | 1 | 44 | 6.5 | 1 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:36:00.229463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990170 | REC_0013051 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.5 | 50 | female | 0 | 63 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:36:00.229779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888234 | REC_0013052 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 12.8 | 62 | male | 0 | 22 | 3.7 | 0 | osimertinib 80 mg daily | 57.1 | false | MSS | 2026-03-15T05:36:00.230119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507710 | REC_0013053 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.2 | 69 | female | 1 | 16 | 4.4 | 3 | alectinib 600 mg BID | 13.7 | false | MSS | 2026-03-15T05:36:00.230611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156512 | REC_0013054 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.8 | 74 | female | 1 | 13 | 5 | 4 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:00.230950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896977 | REC_0013055 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 11.9 | 70 | male | 0 | 10 | 5.9 | 0 | alectinib 600 mg BID | 42.6 | true | MSI-H | 2026-03-15T05:36:00.231279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744497 | REC_0013056 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.1 | 71 | male | 1 | 59 | 6.2 | 10 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:36:00.231632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588045 | REC_0013057 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14 | 74 | female | 2 | 7 | 6.7 | 4 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:00.232010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104255 | REC_0013058 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.2 | 67 | female | 1 | 11 | 2.2 | 4 | sotorasib 960 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.232474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762716 | REC_0013059 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.8 | 64 | male | 0 | 10 | 5.6 | 5 | entrectinib 600 mg daily | 16 | true | MSI-H | 2026-03-15T05:36:00.232896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310344 | REC_0013060 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 10.3 | 58 | female | 0 | 17 | 5.9 | 1 | alectinib 600 mg BID | 28 | false | MSS | 2026-03-15T05:36:00.233293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622246 | REC_0013061 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.9 | 66 | female | 0 | 14 | 5.9 | 4 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:00.233670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669895 | REC_0013062 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 8.5 | 69 | female | 0 | 19 | 4.5 | 1 | alectinib 600 mg BID | 27.2 | false | MSS | 2026-03-15T05:36:00.234033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688889 | REC_0013063 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8.8 | 64 | female | 1 | 34 | 6.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 19.6 | false | MSS | 2026-03-15T05:36:00.234414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546603 | REC_0013064 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 5.7 | 68 | female | 0 | 18 | 6.8 | 7 | sotorasib 960 mg daily | 16.8 | true | MSS | 2026-03-15T05:36:00.234765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100256 | REC_0013065 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 10.9 | 59 | female | 0 | 10 | 7.1 | 5 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:36:00.235093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196600 | REC_0013066 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 16.2 | 60 | female | 0 | 10 | 8.2 | 6 | entrectinib 600 mg daily | 16 | true | MSS | 2026-03-15T05:36:00.235544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763905 | REC_0013067 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.1 | 60 | female | 1 | 17 | 8.7 | 7 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:36:00.235917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420590 | REC_0013068 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.1 | 55 | male | 0 | 6 | 7.1 | 1 | sotorasib 960 mg daily | 20 | true | MSS | 2026-03-15T05:36:00.236381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883648 | REC_0013069 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.1 | 80 | female | 2 | 52 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:36:00.236886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803747 | REC_0013070 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.5 | 61 | female | 0 | 52 | 4 | 2 | pembrolizumab 200 mg q3w | 20.7 | false | MSS | 2026-03-15T05:36:00.237303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639443 | REC_0013071 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 11.6 | 55 | female | 0 | 14 | 4.2 | 6 | pembrolizumab 200 mg q3w | 4.9 | false | MSI-H | 2026-03-15T05:36:00.237701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754959 | REC_0013072 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 13.1 | 72 | female | 1 | 6 | 4.8 | 1 | entrectinib 600 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:00.238057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368803 | REC_0013073 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 13 | 63 | female | 0 | 18 | 5.7 | 2 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:36:00.238436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767888 | REC_0013074 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.2 | 64 | female | 0 | 9 | 5.9 | 5 | osimertinib 80 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:36:00.238877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363083 | REC_0013075 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.9 | 58 | female | 0 | 15 | 4.8 | 2 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:00.239269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717098 | REC_0013076 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 6.9 | 55 | female | 1 | 17 | 4.8 | 4 | alectinib 600 mg BID | 18.6 | true | MSS | 2026-03-15T05:36:00.240531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350829 | REC_0013077 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.7 | 65 | female | 0 | 23 | 2.5 | 6 | alectinib 600 mg BID | 8.7 | true | MSS | 2026-03-15T05:36:00.241376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981185 | REC_0013078 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.8 | 53 | female | 0 | 27 | 4.2 | 5 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:36:00.241796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963642 | REC_0013079 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.1 | 71 | male | 2 | 18 | 7.2 | 8 | osimertinib 80 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:36:00.242336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194975 | REC_0013080 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 62 | female | 0 | 28 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:00.242712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944679 | REC_0013081 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 4.1 | 57 | female | 1 | 17 | 4.5 | 7 | pembrolizumab 200 mg q3w | 5 | true | MSS | 2026-03-15T05:36:00.243065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234447 | REC_0013082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9.9 | 58 | male | 1 | 13 | 4.1 | 6 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:00.243415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844396 | REC_0013083 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.2 | 75 | female | 2 | 7 | 5.1 | 8 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:00.243769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764522 | REC_0013084 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.8 | 70 | female | 3 | 18 | 3.5 | 1 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:36:00.244500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945022 | REC_0013085 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.4 | 64 | female | 1 | 10 | 5.1 | 5 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:36:00.245164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195924 | REC_0013086 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.6 | 77 | female | 1 | 17 | 7.2 | 7 | alectinib 600 mg BID | 15.3 | true | MSI-H | 2026-03-15T05:36:00.245577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794009 | REC_0013087 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.6 | 66 | male | 0 | 63 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:36:00.245944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486872 | REC_0013088 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.1 | 64 | male | 1 | 16 | 6.4 | 2 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:00.246923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570018 | REC_0013089 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.6 | 73 | female | 2 | 57 | 5.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:36:00.251664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778735 | REC_0013090 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.8 | 77 | female | 2 | 12 | 6.2 | 6 | alectinib 600 mg BID | 9.6 | false | MSS | 2026-03-15T05:36:00.252010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158316 | REC_0013091 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 62 | male | 0 | 77 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:36:00.252502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792642 | REC_0013092 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.7 | 59 | female | 1 | 66 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:36:00.253076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993754 | REC_0013093 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 10.2 | 69 | female | 1 | 10 | 4.8 | 1 | sotorasib 960 mg daily | 33.2 | true | MSS | 2026-03-15T05:36:00.253497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782212 | REC_0013094 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.4 | 60 | male | 1 | 11 | 5.7 | 3 | alectinib 600 mg BID | 16.5 | false | MSS | 2026-03-15T05:36:00.253876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588893 | REC_0013095 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 14.7 | 58 | male | 0 | 7 | 4.4 | 5 | osimertinib 80 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:36:00.254330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383755 | REC_0013096 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 15.6 | 50 | male | 0 | 26 | 4.6 | 1 | alectinib 600 mg BID | 29.8 | false | MSI-H | 2026-03-15T05:36:00.254762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474987 | REC_0013097 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 12.5 | 59 | female | 1 | 9 | 6.7 | 2 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:00.255247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332909 | REC_0013098 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 9.6 | 67 | male | 0 | 48 | 5.7 | 6 | pembrolizumab 200 mg q3w | 8.2 | true | MSS | 2026-03-15T05:36:00.255673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704509 | REC_0013099 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.7 | 62 | female | 1 | 20 | 5.2 | 5 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:00.256048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187153 | REC_0013100 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 8.7 | 69 | female | 1 | 13 | 6.6 | 4 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:36:00.256485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.